AE Wealth Management LLC holds $3.63 million in shares of Hologic, Inc. (NASDAQ:HOLX)

AE Wealth Management LLC increased its stake in Hologic, Inc. (NASDAQ:HOLX – Get a rating) by 34.7% in the first quarter, according to the company in its latest 13F filing with the SEC. The institutional investor held 47,241 shares of the medical device supplier after buying an additional 12,175 shares during the quarter. AE Wealth Management LLC’s holdings in Hologic were worth $3,629,000 when it last filed with the SEC.

Several other hedge funds also changed their positions in the company. Fieldpoint Private Securities LLC increased its stake in Hologic shares by 61.4% in Q1. Fieldpoint Private Securities LLC now owns 334 shares of the medical equipment supplier valued at $26,000 after buying 127 additional shares in the last quarter. Bessemer Group Inc. increased its position in Hologic shares by 8.1% during the 4th quarter. Bessemer Group Inc. now owns 2,074 shares of the medical equipment supplier worth $158,000 after buying 156 additional shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its position in Hologic shares by 17.2% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,104 shares of the medical equipment supplier worth $85,000 after buying an additional 162 shares last quarter. Summit Global Investments increased its position in Hologic shares by 0.8% during the 4th quarter. Summit Global Investments now owns 20,655 shares of the medical equipment supplier worth $1,581,000 after buying an additional 162 shares in the last quarter. Finally, NorthCrest Asset Management LLC increased its position in Hologic shares by 2.7% during the 1st quarter. NorthCrest Asset Management LLC now owns 6,780 shares of the medical equipment supplier worth $521,000 after buying an additional 180 shares last quarter. Institutional investors hold 92.70% of the company’s shares.

Shares of NASDAQ HOLX opened at $70.14 on Friday. The company has a market capitalization of $17.49 billion, a PE ratio of 11.56, a growth price-earnings ratio of 0.89 and a beta of 1.09. The company has a current ratio of 2.97, a quick ratio of 2.57 and a debt ratio of 0.59. Hologic, Inc. has a 1-year low of $66.58 and a 1-year high of $81.04. The company’s 50-day moving average is $73.25 and its 200-day moving average is $73.33.

Hological (NASDAQ:HOLX – Get a rating) last released its quarterly earnings data on Wednesday, April 27. The medical equipment supplier reported earnings per share of $2.07 for the quarter, beating the consensus estimate of $1.55 by $0.52. The company posted revenue of $1.44 billion for the quarter, compared to analysts’ estimates of $1.28 billion. Hologic had a net margin of 28.79% and a return on equity of 42.26%. In the same quarter last year, the company achieved EPS of $2.59. As a group, equity research analysts expect Hologic, Inc. to post earnings per share of 5.54 for the current fiscal year.

A number of brokerages have recently released reports on HOLX. StockNews.com began covering Hologic shares in a research report on Thursday, March 31. They set a “buy” rating for the company. SVB Leerink raised its price target on Hologic stock to $85.00 and gave the stock an “outperform” rating in a Tuesday, May 17 research report. Wells Fargo & Company cut Hologic shares from an “overweight” rating to an “equal weight” rating and lowered its target price for the stock from $90.00 to $75.00 in a research report Monday, April 25. Finally, Citigroup lowered its price target on Hologic shares from $78.00 to $75.00 in a Thursday, April 28 report. Four equity research analysts gave the stock a hold rating and six gave the company a buy rating. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $81.00.

In other Hologic news, an insider John Verstreken sold 6,500 shares of the company in a transaction that took place on Tuesday, May 17. The shares were sold at an average price of $78.80, for a total transaction of $512,200.00. Following the sale, the insider now directly owns 64,191 shares of the company, valued at approximately $5,058,250.80. The sale was disclosed in a filing with the Securities & Exchange Commission, accessible via this link. Insiders of the company own 1.54% of the shares of the company.

Hologic Company Profile (Get a rating)

Hologic, Inc develops, manufactures and supplies diagnostic products, medical imaging systems and surgical products for women’s health through early detection and treatment in the United States, Europe, Asia Pacific and the international. It operates through four segments: Diagnostics, Breast Health, Gynecological Surgery and Skeletal Health.

Featured articles

Want to see which other hedge funds hold HOLX? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Hologic, Inc. (NASDAQ:HOLX – Get a rating).

Get news and reviews for Hologic Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Hologic and related companies with MarketBeat.com’s free daily email newsletter.